Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 35
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2095IRF1RNAsHumanUpregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticCancer v/s Normal FDR <0.01Cells26811688
2096GBP1RNAsHumanUpregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticNormal vs HCC FDR <0.01Cells26811688
2097ICAM1RNAsHumanUpregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticNormal vs HCC FDR <0.01Cells26811688
2098Foxa1RNAsHumanDownregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticNormal vs HCC FDR <0.01Cells26811688
2099DHCR7RNAsHumanDownregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticNormal vs HCC FDR <0.01Cells26811688
2100HMGCS2RNAsHumanDownregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticNormal vs HCC FDR <0.01Cells26811688
2101MSMO1RNAsHumanDownregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticNormal vs HCC FDR <0.01Cells26811688
2132CYP3A4ProteinHumanUpregulated in in hepatitis B virus-associated liver cirrhosis and stage I hepatocellular carcinoma, PrognosticHCC vs adjacent non-tumor and stageII v/s stage-III; predict early stage p < 0.05Tissue and Cells 23891548
2167CORO1CProteinHumanUpregulated in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis and higher coronin-1C expression had more advanced stage in patients PrognosticAgressive or advanced-stage HCC v/s less-aggressive HCC; predict metastatic stage p < 0.05Tissue and Cells 20181269
2168CYP1A1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2169CYP1B1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2170GDF15RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2171SERPINE1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2172SOS1RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2173RASD1RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2174MRASRNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2175NR1H4RNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2176PALMDRNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2177TXNIPRNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2178miR-122miRNAHumanvariable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in Diagnostic and PrognosticNormal vs HCC; associated with survival, tumor size and differentiation status p < 0.001Tissue and Cells 19617899
2198miR-26amiRNAHuman cell lineDownregulated in HepG2 cells Potential Diagnostic *Normal cell line vs Liver cancer cell line p < 0.05Cells29430178
2266AURKB-Sv2 variantRNAsHumanUpregulated in metastatic HCC than primary HCC and Absent in normal PrognosticMetastatic HCC v/s Primary HCC; correlated with a poor outcome and short disease-free period p < 0.01Cell line and Tissue19134008
2361UBA2RNAsHuman cell lineUpregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2362ZNF185RNAsHuman cell lineUpregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2363FOXF1RNAsHuman cell lineUpregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2364UBE4BRNAsHuman cell lineDownregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2428IGFBP7Protein and RNAsHumanDownregulated in IFN-resistant cells (with fold change 2.963) PredictiveIGFBP7-positive HCC patients v/s IGFBP7-negative HCC patients p < 0.05Cell line and Tissue20407444
2463CLURNAsHumanUpregulated in metastatic HCC than primary HCC Diagnostic and PrognosticPrimary and metastatic HCC p < 0.001Cell line and Tissue16247463
2498TGM2ProteinHumanUpregulated in HCC than non tumor DiagnosticHCC v/s normal p < 0.05Cell line, Tissue, Serum18646787
2507SGCERNAsHumanUpregulated in HCC than non-tumor (with > 3 fold change) DiagnosticHCC v/s non-tumor p < 0.05Cell line, Tissue19171046
2508PEG10RNAsHumanUpregulated in HCC than non-tumor (with > 3 fold change) DiagnosticHCC v/s non-tumor p < 0.05Cell line, Tissue19171046
2509CCL20, S100P, PEG10, SGCE, XAGE-1, COL4A1, ZNF83, and TM4SF1RNAsHumanUpregulated in HCC than non-tumor (with > 3 fold change) DiagnosticHCC v/s non-tumor p < 0.05Cell line, Tissue19171046
2517FGGProteinHumanDownregulated in HCC than non-tumor (with 100 fold change) DiagnosticHCC v/s non-tumor p < 0.05Cell line, Tissue16980951
2518FGL1ProteinHumanDownregulated in HCC than non-tumor (with 100 fold change) DiagnosticHCC v/s non-tumor p < 0.05Cell line, Tissue16980951
2519Alpha-2-plasmin inhibitor, SERPINF2ProteinHumanDownregulated in HCC than non-tumor (with 100 fold change) DiagnosticHCC v/s non-tumor p < 0.05Cell line, Tissue16980951

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top